Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
复制标题
DOI：
10.1016/j.amjcard.2007.03.005
复制
发表时间：
2007-07-18
影响因子：
2.8
通讯作者：
Basile, Jan N.
中科院分区：
文献类型：
--
作者：
Cushman, William C.;Grimm, Richard H., Jr.;Basile, Jan N.
控制糖尿病心血管疾病的行动（雅阁）血压试验是一项非盲、开放标签、随机试验，样本量为4，733例受试者。本报告描述了雅阁中血压干预的原理、设计和方法。符合血压试验条件的参与者被随机分配到两组中的一组，每组具有不同的治疗目标：收缩压< 120 mm Hg为更密集的目标，收缩压< 140 mm Hg为较不密集的目标。该试验的主要结局指标是在4-8年的随访期间首次发生重大心血管疾病（CVD）事件，特别是非致死性心肌梗死或卒中或心血管死亡。雅阁血压试验应提供第一个明确的临床试验数据，说明更积极的收缩压目标治疗在减少糖尿病患者CVD事件方面的可能获益。(c)2007爱思唯尔公司All rights reserved.
The Action to Control Cardiovascular Disease in Diabetes (ACCORD) blood pressure trial is an unmasked, open-label, randomized trial with a sample size of 4,733 participants. This report describes the rationale, design, and methods of the blood pressure interventions in ACCORD. Participants eligible for the blood pressure trial are randomized to 1 of 2 groups with different treatment goals: systolic blood pressure < 120 mm Hg for the more intensive goal and systolic blood pressure < 140 mm Hg for the less intensive goal. The primary outcome measure for the trial is the first occurrence of a major cardiovascular disease (CVD) event, specifically nonfatal myocardial infarction or stroke, or cardiovascular death during a follow-up period ranging from 4-8 years. The ACCORD blood pressure trial should provide the first definitive clinical trial data on the possible benefit of treating to a more aggressive systolic blood pressure goal in reducing CVD events in patients with diabetes mellitus. (c) 2007 Elsevier Inc. All rights reserved.